A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Additional inclusion/exclusion criteria may apply, per protocol.
info-clinicalstudies@kailera.com1-781-317-0291
Ciudad Autonoma de Buenos Aires, Buenos Aires 1120, Argentina
CABA, 1061, Argentina
Sofia, Sofia 1606, Bulgaria
Sofia, Sofia 1618, Bulgaria
Nawton, Hamilton 3200, New Zealand